Canadian Cancer Trials Group Senior Investigator Jonathan Loree is a medical oncologist at BC Cancer, Associate Professor at The University of British Columbia and Senior Investigator at CCTG with an interest in GI malignancies. He completed his medical oncology fellowship at BC Cancer and subsequently undertook a translational research fellowship at MD Anderson where he completed a Master of Science. His research focus is translational research and biomarker development in colorectal cancer and neuroendocrine neoplasms. He serves as the NCI Colon Cancer Task Force Co-Chair and is a member of the ASCO Evidence Based Medicine Committee.Areas of expertise: gastrointestinal cancers, correlative sciencesResearch interests: genomics, translational research, biomarker development, colorectal cancer, neuroendocrine neoplasms, circulating tumor DNACurrent trials: CO28, CO29, CO32, CRC10Selected Publications: Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, Cho MT, Cusnir M, Dorth J, George M, Kachnic LA, Kennecke HF, Loree JM, Morris VK, Perez RO, Smith JJ, Strickland MR, Gholami S. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol. 2024 Oct;42(28):3355-3375. doi: 10.1200/JCO.24.01160. Epub 2024 Aug 8. PubMed PMID: 39116386.Loree JM, Titmuss E, Topham JT, Kennecke HF, Feilotter H, Virk S, Lee YS, Banks K, Quinn K, Karsan A, Renouf DJ, Jonker DJ, Tu D, O'Callaghan CJ, Chen EX. Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial. Clin Cancer Res. 2024 Aug 1;30(15):3189-3199. doi: 10.1158/1078-0432.CCR-24-0268. PubMed PMID: 38727700; PubMed Central PMCID: PMC11292199.Topham JT, O'Callaghan CJ, Feilotter H, Kennecke HF, Lee YS, Li W, Banks KC, Quinn K, Renouf DJ, Jonker DJ, Tu D, Chen EX, Loree JM.Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer. J Clin Oncol. 2023 Jan 20;41(3):485-496. doi: 10.1200/JCO.22.00364. Epub 2022 Aug 25. PubMed PMID: 36007218; PubMed Central PMCID: PMC9870216.Kennecke HF, O'Callaghan CJ, Loree JM, Moloo H, Auer R, Jonker DJ, Raval M, Musselman R, Ma G, Caycedo-Marulanda A, Simianu VV, Patel S, Pitre LD, Helewa R, Gordon VL, Neumann K, Nimeiri H, Sherry M, Tu D, Brown CJ. Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results. J Clin Oncol. 2023 Jan 10;41(2):233-242. doi: 10.1200/JCO.22.00184. Epub 2022 Aug 18. PubMed PMID: 35981270; PubMed Central PMCID: PMC9839227.Renouf DJ, Loree JM, Knox JJ, Topham JT, Kavan P, Jonker D, Welch S, Couture F, Lemay F, Tehfe M, Harb M, Aucoin N, Ko YJ, Tang PA, Ramjeesingh R, Meyers BM, Kim CA, Du P, Jia S, Schaeffer DF, Gill S, Tu D, O'Callaghan CJ. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat Commun. 2022 Aug 26;13(1):5020. doi: 10.1038/s41467-022-32591-8. PubMed PMID: 36028483; PubMed Central PMCID: PMC9418247.For a full list of publications please visit https://www.ncbi.nlm.nih.gov/myncbi/jonathan.loree.1/bibliography/public/Awards: 2022 CCTG Dr. Ralph Meyer Phase III Young Investigator Award2022 University of British Columbia Donald M Whitelaw Award for Outstanding Grand Rounds 2023 Current Oncology Young Investigator Award – International Award for Excellence in the Field of Oncology Research
